<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FLUVASTATIN</span><br/>(flu-vah-stat'in)<br/><span class="topboxtradename">Lescol, Lescol XL<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">antilipemic</span>; <span class="classification">hmg-coa reductase inhibitor (statin)</span><br/><b>Prototype: </b>Lovastatin<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>20 mg, 40 mg capsules; 80 mg extended release tablet</p>
<h1><a name="action">Actions</a></h1>
<p>Inhibits therapeutic reductase 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA), which is essential to hepatic production of
         cholesterol. Cholesterol-lowering effect triggers induction of LDL receptors, which promotes removal of LDL and VLDL remnants
         (precursors of LDL) from plasma.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Results in an increase in plasma HDL concentration. HDLs collect excess cholesterol from body cells and transport it to the
         liver for excretion.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct to diet for the reduction of elevated total LDL cholesterol in patients with primary hypercholesterolemia (Types IIa
         and IIb).
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Other types of hyperlipidemias.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to fluvastatin, lovastatin, pravastatin, or simvastatin; active liver disease or unexplained persistent elevated
         liver function tests; pregnancy (category X), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients who consume substantial quantities of alcohol; history of liver disease; renal impairment.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypercholesterolemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 20 mg h.s., may increase up to 80 mg/d in 12 doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give at bedtime.</li>
<li>Ensure the extended release tablet is not chewed or crushed. It must be swallowed whole.</li>
<li>Separate doses of this drug and bile-acid resin (e.g., cholestyramine) by at least 2 h when given concomitantly.</li>
<li> 				Note: Dosage adjustments may be required in patients with significant renal or hepatic impairment. 			</li>
<li>Store at room temperature, 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, fatigue.  <span class="typehead">Body as a Whole:</span> Myalgia. <span class="typehead">GI:</span> Dyspepsia, diarrhea, abdominal pain. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May increase risk of bleeding with <b>warfarin;</b> <b>cholestyramine</b> decreases fluvastatin absorption; <b>rifampin</b> increases metabolism of fluvastatin; may increase risk of myopathy and rhabdomyolysis with <b>gemfibrozil,</b> <b>fenofibrate,</b> <b>clofibrate.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract; about 24% reaches systemic circulation after first-pass metabolism <span class="typehead">Onset:</span> 36 wk. <span class="typehead">Peak:</span> Serum level 0.51 h. <span class="typehead">Distribution:</span> 98% protein bound; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 95% excreted in bile; 5% excreted in urine. <span class="typehead">Half-Life:</span> 0.51 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor lipoprotein levels; maximal lipid-lowering effect occurs in 46 wk. Monitor serum transaminase and
            CPK levels every 34 mo for the first year and periodically thereafter.
         </li>
<li>Monitor PT &amp; INR in patients on concurrent warfarin therapy; PT &amp; INR may be prolonged.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take fluvastatin at bedtime.</li>
<li>Be alert &amp; report signs of bleeding immediately when also taking warfarin.</li>
<li>Notify physician immediately of the following: Fever; rash; muscle pain, weakness, tenderness, or cramping.</li>
<li>Reduce or eliminate alcohol consumption while taking fluvastatin.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>